Past Meeting| Keystone Symposia

Web Desc
HIV Vaccines Organizer(s): Andrew B. Ward, Penny L. Moore and Robin Shattock Date: March 26 - 30, 2017 Location: Sheraton Steamboat Resort, Steamboat Springs, CO, USA Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation. Summary of Meeting: Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity. Global Health Travel Award Deadline: October 25 2016 Scholarship Deadline: November 29 2016 Discounted Abstract Deadline: November 29 2016 Abstract Deadline: January 10 2017 Discounted Registration Deadline: January 24 2017 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Kymab Limited We gratefully acknowledge the generous grant for this conference provided by: National Institute of Allergy and Infectious Diseases (NIAID) Grant No. 1R13AI129592-01 Funding for this conference was made possible (in part) by AI29592-01 from the National Institute of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

HIV Vaccines

Organizer(s): Andrew B. Ward, Penny L. Moore and Robin Shattock

Date: March 26 - 30, 2017
Location: Sheraton Steamboat Resort, Steamboat Springs, CO, USA

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Summary of Meeting:

Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.

Global Health Travel Award Deadline: October 25 2016

Scholarship Deadline: November 29 2016

Discounted Abstract Deadline: November 29 2016

Abstract Deadline: January 10 2017

Discounted Registration Deadline: January 24 2017

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Kymab Limited

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI129592-01
Funding for this conference was made possible (in part) by AI29592-01 from the National Institute of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found